icant variations were noted among CAMHB lots (modes at 0.004 [1 lot] or 0.008 g/ml [3 lots]) or for the study sites with modal occurrences at 0.008 g/ml for four participants, as well as one and three occurrences at 0.015 and 0.004 g/ml, respectively. The geometric mean of all S. aureus ATCC 29213 MIC values was 0.007 g/ml.
A total of 99.7% of S. aureus ATCC 29213 MIC results were included in the proposed Debio 1452 QC range of 0.002 to 0.015 g/ml. The number of MIC values at 0.004 g/ml represented 70.6% of the number of modal MIC results (0.008 g/ml); therefore, a 4-dilution range was calculated as instructed in the CLSI M23-A3 document (8) . Data from the study were also analyzed by the Range Finder program (11) , and that statistical method confirmed the proposed range, without detecting any significant outlier laboratories. All rifampin control MIC results were within the published CLSI range (10), validating technical standards for the reference method (9) . The proposed Debio 1452 QC range with S. aureus ATCC 29213 of 0.002 to 0.015 g/ml was approved by the CLSI Subcommittee on Antimicrobial Susceptibility Testing (CLSI January 2011 meeting minutes).
As methicillin-resistant S. aureus continues to cause serious clinical infections with associated mortality and morbidity, the search for new antimicrobials has become vital (12, 13) . Such new agents should have enhanced activity and potency against these multidrug-resistant staphylococci and possess novel targets, where possible. Debio 1452 is such a new agent directed against the FabI target found in staphylococci (MIC 90 , 0.008 to 0.12 g/ ml) (1) . These MIC quality assurance guidelines (Fig. 1 ) from a multilaboratory investigation provide initial Debio 1452 QC ranges which can be applied as parameters for routine susceptibility testing when utilizing the reference broth microdilution method (9, 10) and as this new bacterial FabI inhibitor is being developed for oral and intravenous treatment of acute bacterial skin and skin structure infections (7) .
